Sentence examples for efficacy assay from inspiring English sources
In vivo antitumor efficacy assay in human tumor xenograft model revealed that only when the entire organ, cellular and sub-cellular level barriers had been broken down, will Onconase turn into a potent antitumor agent.
The results of transfection efficacy assay demonstrated the optimal FPBAE could mediated much higher GFP expression than the commercial transfection agents, polyethyleneimine (PEI, Mw = 25K) and Lipo 2000, as well as the non-fluorinated poly(β-amino ester)s (PBAE) on both HeLa and HEK-293T cell lines (higher than 70 and 90%, respectively), which was largely attributed to fluorination.
With the objective of extending the usage of A2-tansgenic mouse in vaccine efficacy assay, here, we established a B16 tumor cell line coexpressing HLA-A*0201/H-2Kb chimeric gene and a polyepitope construct based on the use of a mammalian expression vector pIRES.
Fisher's exact two-sided test was used to analyze numbers of mice infected and uninfected in test groups vs control groups in the protective efficacy assay.
The efficacy assay of HIV-1 PV infection by inverted fluorescence microscopy with FITC-labeled anti-HIV-1 p24 antibody demonstrated that more than 90% MDM cells were infected by the virus, but not the mock-infected control (Fig. 1A), indicating that uniform infection of the MDM cells by HIV-1 PV implemented.
From the anticancer efficacy assay utilizing human cervical cancer cell, HeLa, we found that the nanohybrids showed higher drug efficacy compared with free drug only.
In in vivo efficacy assays, lentiviral circuit delivery mediated significant tumor reduction and prolonged mouse survival.
The non-irritant and adequate safety profile under sun-exposed skin conditions of the nanomaterials and the emulsions qualified the products for clinical efficacy assays.
We designed and synthesized multiply protected dimeric analogs of pyrrhocoricin and optimized the in vitro antibacterial efficacy assays for peptide antibiotics.
Finally, we conducted two in vivo efficacy assays using the Coding-PPRH against the survivin promoter and performing two routes of administration, namely intratumoral and intravenous, in a subcutaneous xenograft tumor model of PC3 prostate cancer cells.
It is reasoned through experimental evidence that greater understanding of the mechanics of cancer cell deformability and its interactions with the extracellular physical, chemical and biological environments offers enormous potential for significant new developments in disease diagnostics, prophylactics, therapeutics and drug efficacy assays.
